Wednesday, July 29, 2020
Onconova Therapeutics Inc. (ONTX)
What is going on with Onconova?
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Funding application to use rigosertib against coronavirus infection. This week, Onconova has submitted an application to the National Institute of Allergy and Infectious Disease (NIAID), to obtain funding from the National Institutes of Health (NIH) to conduct human studies with rigosertib for the treatment of COVID-19 disease. The company plans to pursue clinical studies upon a positive funding decision.
What does it mean? The company plans to pursue clinical studies only upon a positive funding decision. While it is not easy to predict the NIAID’s decision to fund rigosertib to treat coronavirus infection, Onconova does not intend to pursue clinical development without additional sources. A favorable decision would …
Click to get the full report
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
